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Patients’ and caregivers’ experiences of
using continuous glucose monitoring to
support diabetes self-management:
qualitative study
J. Lawton1*, M. Blackburn1, J. Allen2,3, F. Campbell4, D. Elleri5, L. Leelarathna6, D. Rankin1, M. Tauschmann2,3,
H. Thabit6 and R. Hovorka2,3
Abstract
Background: Continuous glucose monitoring (CGM) enables users to view real-time interstitial glucose readings and
provides information on the direction and rate of change of blood glucose levels. Users can also access historical data
to inform treatment decisions. While the clinical and psychological benefits of CGM are well established, little is known
about how individuals use CGM to inform diabetes self-management. We explored participants’ experiences of using
CGM in order to provide recommendations for supporting individuals to make optimal use of this technology.
Methods: In-depth interviews (n = 24) with adults, adolescents and parents who had used CGM for ≥4 weeks; data
were analysed thematically.
Results: Participants found CGM an empowering tool because they could access blood glucose data effortlessly, and
trend arrows enabled them to see whether blood glucose was rising or dropping and at what speed. This predicative
information aided short-term lifestyle planning and enabled individuals to take action to prevent hypoglycaemia and
hyperglycaemia. Having easy access to blood glucose data on a continuous basis also allowed participants to develop
a better understanding of how insulin, activity and food impacted on blood glucose. This understanding was described
as motivating individuals to make dietary changes and break cycles of over-treating hypoglycaemia and hyperglycaemia.
Participants also described how historical CGM data provided a more nuanced picture of blood glucose control than
was possible with blood glucose self-monitoring and, hence, better information to inform changes to background
insulin doses and mealtime ratios. However, while participants expressed confidence making immediate adjustments to
insulin and lifestyle to address impending hypoglycaemia and hypoglycaemia, most described needing and expecting
health professionals to interpret historical CGM data and determine changes to background insulin doses and mealtime
ratios. While alarms could reinforce a sense of hypoglycaemic safety, some individuals expressed ambivalent views,
especially those who perceived alarms as signalling personal failure to achieve optimal glycaemic control.
Conclusions: CGM can be an empowering and motivational tool which enables participants to fine-tune and optimize
their blood glucose control. However, individuals may benefit from psycho-social education, training and/or
technological support to make optimal use of CGM data and use alarms appropriately.
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Background
Continuous glucose monitoring (CGM) enables users
to view real-time interstitial glucose readings and pro-
vides information on the direction and rate of change
of blood glucose levels. Multiple alarms can be set to
alert users if blood glucose either rises or falls (or is
predicted to rise or fall) beyond predefined target
ranges, and individuals are able to access historical
data to inform diabetes self-management decisions.
CGM is associated with reductions in glycated haemo-
globin (HbA1c) levels in both adults and children,
especially when used frequently [1–4]. CGM has also
been shown to reduce hypoglycaemia and hypergly-
caemia [2, 3, 5], severe hypoglycaemia [6]; and, im-
prove treatment satisfaction [7–9] and quality of life
outcomes [10, 11].
While the clinical and psychological benefits of CGM are
well established, less is known about how individuals use
CGM to make informed treatment decisions and why high
levels of treatment satisfaction exist. Only limited qualita-
tive research, focusing on user and/or caregiver experi-
ences, has been conducted. This includes work exploring
barriers to using, and reasons for discontinuing, CGM in
adolescent [12] and adult groups [13]; adult users’ attitudes
and characteristics which might help predict effective use
of CGM [14]; and, how use of CGMmay influence couple’s
diabetes management and marital relationships [15]. More
recently, Pickup et al. [16] used an open-ended survey
question to explore user and caregiver experiences of
CGM, including benefits and drawbacks encountered.
While this is the most comprehensive study in terms of
scope and sampling, Pickup et al.’s design did not permit
user experiences to be explored in detail; hence, they rec-
ommended further, in-depth research be undertaken [16].
In line with this recommendation, we conducted in-depth
interviews with individuals (adults, adolescents and par-
ents) who made nonadjunctive use of CGM over ≥4 weeks
in the initial training phase of a closed-loop study. The aim
of this interview study was to understand and explore
how participants used CGM to support diabetes self-
management and what they considered the main benefits
and drawbacks to be. Our objectives were to aid interpret-
ation of findings from earlier CGM studies; and, provide
recommendations for supporting individuals using CGM.
An additional objective was to collect data to allow com-
parisons to be drawn with participants’ later experiences
of using a closed-loop system as part of the trial; these
data will be reported separately.
Methods
Participants and devices
Inclusion criteria for trial enrolment included a screen-
ing HbA1c ≥7.5% (58.5 mmol/mol) and ≤10% (86 mmol/
mol) and a diabetes duration of at least 6 months [17].
Individuals were required to have used an insulin pump
for at least 3 months, with good knowledge of insulin
self-adjustment as judged by the investigator [17]. Indi-
viduals were ineligible for the trial if they had used
CGM regularly in the previous three months.
Following trial recruitment, participants were trained
to use the study insulin pump (MiniMed™ 640G pump,
Medtronic, Northridge, CA, USA) and glucose sensor
(Guardian™ Sensor 3, Medtronic by health care profes-
sionals who followed a common outline curriculum. Key
areas covered in the training included: an insertion and
initiation of sensor session, using the sensor menu of the
insulin pump and sensor calibrations, use of software to
analyse CGM data and use of CGM data to optimise
treatment. Written guidelines for the operation and use
of the CGM device were also provided in the form of
the manufacturer’s user manual. Alarm settings on the
CGM device were initially standardized but participants
were allowed to adjust these during the study period.
Parents/caregivers were unable to remote access their
child’s CGM data.
Participants who took part in the interview study com-
prised: individuals aged ≥16 years; individuals aged 13–
15 years and their parent(s)/caregiver(s); and, parents/care-
givers of those aged ≤12 years. The decision to interview
parents/caregivers of those aged ≤12 years and those aged
13–15 years was made because, in younger groups, parents
take responsibility for most diabetes management tasks
[18], while supporting and sharing responsibility with ado-
lescents [19]. Interviewees were invited to take part in the
qualitative study by members of the clinical team in the
four participating UK sites (Cambridge, Manchester, Leeds,
and Edinburgh). The clinical team informed these individ-
uals that the qualitative research was being conducted by
an independent research team and gave them reassurances
of confidentiality. Recruitment and data collection contin-
ued until there was representation of different age groups
in the final sample and data saturation had occurred; that
is, until no new findings were identified in new data col-
lected. The study received approval from the independent
Cambridge East Research Ethics Committee (REC ref. 15/
EE/0324). Participants aged ≥16 years and parents or
guardians of participants aged < 16 years provided signed
informed consent; written assent was obtained from mi-
nors before study-related activities.
Qualitative study design
In-depth interviews were used as the method of data
collection, as these afforded the flexibility needed for
participants to discuss issues they perceived as salient,
including those unforeseen at the study’s outset [20],
while use of topic guides helped ensure the data col-
lected remained relevant to the study aims and objec-
tives. An inductive approach was used informed by
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general principles of Grounded Theory research [21].
This entailed simultaneous data collection and analysis,
with findings from early interviews informing areas ex-
plored in later ones.
Data collection and analysis
Interviews were conducted by MB at a time and location
of participants’ choosing (mostly in their own homes) im-
mediately before they moved into the main phase of the
trial, at which point they had used CGM in real-life situa-
tions for a minimum of 4 weeks. Topic guides were devel-
oped based on literature reviews, input from clinical team
members, and revised in light of emerging findings, in line
with an inductive approach. Key areas explored included:
previous experience of using CGM and self-monitoring of
blood glucose (SMBG); understandings and expectations
of CGM and impact of CGM (if any) on diabetes self-
management; likes and dislikes of the technology; and
views about information and training needed to support
effective use of CGM. Patients aged 13–15 years old and
their parents were interviewed separately. The interviews
took place between July 2016 and May 2017. They typic-
ally lasted 1–2 h, were digitally recorded and transcribed
in full for in-depth analysis.
Data were analysed by three experienced qualitative
researchers (JL, MB and DR) using a thematic ap-
proach informed by the method of constant compari-
son; this entailed cross-comparison of all interviews to
identify recurrent themes, before a coding framework
was developed to capture these themes and contextual
information needed to aid data interpretation. Nvivo, a
qualitative software package, was used to facilitate data
coding and retrieval and coded datasets were subjected
to further analyses to allow more nuanced interpreta-
tions of the data to be developed.
Results
The sample comprised 12 participants aged 16+ years,
three participants aged 13–15 years and nine parents
(see Table 1). A 100% opt-in was achieved. Eighteen in-
terviewees (including six parents of child participants)
described having had prior experiences of using CGM
(e.g. to manage diabetes or as part of an earlier
research study).
Ease of access to continuous data
A key benefit of CGM, as all participants highlighted,
was the ease with which they were able to access infor-
mation about their blood glucose levels. Indeed, it was
precisely because this process was so effortless that par-
ticipants said they were much more aware of what their
(or their child’s) blood glucose levels were throughout
the day than when only SMBG was used:
“It’s so much easier with anything isn’t it, where you
can just glance at it. It’s, you know, if to tell the time,
rather than just glancing at your watch you had to
sort of get something out, open it up, fiddle around
with it, you wouldn’t worry so much about checking
the time, would you?” (Parent 6)
Table 1 Characteristics of study participants
Participants with type 1 diabetes (n = 15)
Gender, female (n,%) 7(46.7)
Age at recruitment (years)
13–15 3
16–20 2
21–30 1
31–40 6
41–50 2
51–60
60+ 1
Occupation/education (n,%)
Professional 5(33.3)
Semi-skilled 4(26.7)
Retired 1(6.7)
Higher education 2(13.3)
Secondary school 3(20)
Self-reported diabetes duration
(mean, SD, range - years)
≤12 years 4 ± 2.9 (2–9)
13–17 9.25 ± 3.9
(4.5–13.75)
18+ 25 ± 11.1
(15–45)
Sensor use run-in
(% over 4 weeks)
≤12 years 81.2 ± 13.8 (64–99)
13–17 85.6 ± 10.8 (77–98)
18+ 89.9 ± 6.4
(77–97)
Parents of paediatric patients
(n = 9)a
Gender, female (n,%) 7(77.8)
Age at recruitment (years)
31–40 2
41–50 5
51–60 2
Occupation (n,%)
Professional 5(55.6)
Semi-skilled 3(33.3)
Unemployed/Full
time Carer
1(11.1)
aThis includes: parents who represented children aged ≤12 years (n = 5) and
parents of children aged 13–15 (n = 4). In one instance, both parents of a child
aged 13–15 participated in an interview
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Indeed, many participants drew a strong contrast be-
tween their experiences of using CGM and those of
SMBG with Participant 3, like others, noting the limita-
tions arising from the latter:
“it’s [SMBG] frustrating.. cause you don’t know what’s
happening … it’s like walking around with a blindfold
on. And you can walk into a room every now and then
and take the blindfold off for 60 seconds. And then you
have to put it back on.”
Predicting and managing the future
As Participant 3 went on to elaborate, SMBG was of
limited benefit not only because one could not instantly
and effortlessly access one’s blood glucose levels, but
also because it was not possible to establish “whether
you’re going up or down, and how fast”. Indeed, a cen-
tral benefit of CGM, as all participants observed, were
the opportunities trend arrows presented to predict the
future by virtue of being able to tell whether their blood
glucose was rising or dropping and at what speed. This
included Participant 1 who discussed how CGM data,
when compared to SMBG results, enabled them to
“make more informed decisions on what you’re going to
do. And probably a lot sooner” because, as they ex-
plained, “I can see ok I’m actually going up. I’m going
up really quickly. Or I’m coming down, I’m coming
down fast, so I need to do something about it. As op-
posed to just a snapshot.”
As various individuals noted, CGM thus helped enable
them to pre-empt and prevent hypo- and hypergly-
caemia, and thereby achieve more stable blood glucose
levels, because, “obviously you’re ready before it hap-
pens” (Parent 2). Specifically, participants discussed how
the predictive information provided by CGM prompted
proactive use of corrective insulin doses or consumption
of carbohydrate to prevent their (or their child’s) blood
glucose levels moving out of target ranges:
“if she [teenaged daughter] says: ‘oh I don’t feel quite
right’, she can glance at it and think: ‘oh yeah I’m
going high and I’ve got an arrow going straight up’.
So she can then say: ‘oh yeah, actually I need to
actually put a bolus in’. And equally if she’s got an
arrow going straight down, she can say: ‘actually
although I’m six, I’ve got an arrow going straight
down. So I need something [to eat] within the next 20
minutes, half an hour, otherwise I’m gonna hypo’. So
that’s good. You can almost stop things happening
before they get to the critical point.” (Parent 6)
Some individuals also discussed how the predictive in-
formation provided by CGM enabled short-term lifestyle
planning, whether this be, as Participant 2 described, by
changing the timing of a meal or, in Participant 7’s case,
reducing the length of a walk, to avoid hypo- or
hyperglycaemia:
“It’s easier to do the stuff I wanna do, because I can
read my pump. I can see: am I going up? Am I going
down? Should I have lunch before I do this? Or can I
do this before lunch kind of thing?... [using CGM] I
can say: oh we’ll have lunch in half an hour. Or I can-
I’ll just finish what I’m doing, or. So I think it’s giving
me more personal freedom if you like.” (Participant 2)
“Yes, the arrow- well that’s good for going low. Em,
it’s a good- great indicator to see that it’s- my sugars
are actually- they’re dropping a little bit faster than I
expected. They’re maybe dropping according to the
graphs, but dropping a lot faster. Em, it means I can
get, if I’m out for a walk with the dog, I can think:
okay. Right I need to cut the walk short, because I’m
going to go low otherwise.” (Participant 7)
While individuals described having received some in-
struction from health professionals on how to interpret
and respond to the information provided by trend ar-
rows, most emphasised that they found this information
to be intuitive and easy to understand and as having
prompted common-sense responses:
“they told me what the arrows mean… But I‘ve- I’ve
kind of taken it upon myself to interpret that into
three arrows and active insulin, get something quick,
and quick-acting. Em so I’ve kind of used what I think
is my best judgement on that.” (Participant 9)
Understanding the impact of lifestyle and insulin on
blood glucose levels
Participants also described how having easy access to
CGM data on a continuous basis had enabled them to
develop a much better understanding of how insulin,
food and physical activity impacted on their blood glu-
cose levels. As several individuals noted, such informa-
tion had been an informative and motivational tool
which had prompted positive changes to how they
had approached and managed their diabetes. This in-
cluded Participant 10 who described how they had
broken a pattern of over-treating hypoglycaemia after
‘real time’ CGM data had provided evidence and reassur-
ance that a more restrained approached was more
efficacious:
“when I’d be treating a low, before I just thought I’ll
just eat and eat. And, obviously the sensor showed me
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that when I did that I would just bounce way way
back up, too high, because before, you know, I
couldn’t physically see [this] on my pump with the
arrows .. So now I know that I just- I can’t eat- I just
don’t need to eat as much. I don’t need to panic as
much.”
Participant 14, likewise, described adopting a more
“patient” approach to their diabetes self-management
in light of information provided by CGM, one which
meant they were now less likely to over-correct for
hyperglycaemia:
“So when I’ve used the pump to correct for it
[high blood glucose] and I can see [from ‘real time’
CGM data], well actually I probably won’t need to,
I can probably be a bit more patient and wait for it to
catch up. And that’s quite helpful because that means
I am less likely to have a hypo as a result of
overcorrecting.”
In another pertinent example, Parent 2 noted how her
12 year old daughter has been motivated to make dietary
changes after CGM data had alerted her to how con-
sumption of high sugar foods, such as breakfast cereals,
were causing her blood glucose to spike:
“she herself, off her own back, has been able to see,
physically see on the line, where something has
affected her blood sugar. Whereas before it will have
affected it, and, you know, we treat it. But .. cause
it’s a visual line she can see, that eating something’s
gonna make her shoot up- it’s kind of- I think it’s
struck a chord, in that she’s going: ‘well actually,
that’s not really that good’. So she’s making conscious
decisions in what she chooses to eat, without any kind
of enforcement or- or guiding… changed the type of
breakfast she has, so that she- she’s been having more
smoothies rather than these high sugar, carby
breakfasts.”
Using the past to improve the future; retrospective
analysis of data
Participants also discussed how the retrospective data
provided by CGM enabled them to develop insight into
their blood glucose control at times when they were
much less likely to undertake SMBG, principally when
they were asleep. In some cases, being able to examine
graphs of night-time readings offered peace of mind that
in target and stable blood glucose control was being
achieved. In others, such as Participant 14, retrospective
review of CGM data had alerted participants to un-
known problems with their blood glucose control:
“And you can see what the history’s like and the trends
and stuff. And I find that really, really helpful, because
it’s like looking back over the period you’ve been asleep.
And you can see what your blood sugar’s been doing...
Sometimes you go to bed with a really normal blood
sugar and you wake up and it’s normal. But over the
night it’s just done this. And it’s like: ‘Wow’. Before I
would have thought: ‘ah pretty good control really
(laughs). But there’s something weird happening in the
middle of the night.’” (Participant 14)
As participants also discussed, having access to graphs
which captured historical data provided useful informa-
tion which could be used to inform changes to basal
rates and/or mealtime ratios:
“So you know, retrospectively you can look up the
past couple of weeks and have a look at each day and
you can see much better the patterns that come from
your blood sugars and then you can adjust your
insulin far more easily. … if you can see a pattern
from the CGM charts I can change those instantly,
the basal patterns and the ratios far more easily.. to
get better stable control.” (Participant 3)
Indeed, while participants did note that it was possible
to generate data for retrospective analysis using SMBG,
because CGM captured data at five minute intervals, it
also allowed a much more nuanced and informative pic-
ture to be generated than could be captured through
periodic snapshots:
“Em, but since I’ve had the sensor, because I’ve got
continuous points I’m getting a nice clean graph,
rather than working off five or six points a day.
So I’m able to make a lot better decision, rather than
having to check my sugars every 30 minutes to try to
get a nice trend pattern, I’m now getting a really good
set of results that I can work off.” (Participant 7)
Independent and dependent adjustments
However, while participants, including Participant 7,
noted the value of the retrospective information pro-
vided by CGM, only a minority described having the
confidence and ability to use this information to make
independent adjustments to pump settings (basal rates)
and/or meal time ratios. Indeed, in line with their earlier,
pre-trial experiences of using insulin pumps (without
CGM) where participants reported experiencing similar
difficulties, the majority described both needing and
expecting input and help from health professionals prior
to changing basal rates and meal ratios. This was not
only because participants questioned their own numeric
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skills and ability to analyse CGM data, but also because
deferring to health professional expertise appeared, for
many, to have been a habituated, taken-for-granted prac-
tice which pre-dated their use of CGM:.
“It’s quite- a quite complicated set up. So yes I have
different basal rates, for different times. And we do
change that. I don’t change it on my own...it’s not
something I’d do without talking to some other clever
girls…. only because I think it is so fundamental of
my regime, that I would be worried about changing it
without understanding 100% if it should be up or
down. So it’s more insecurity I think, of my own
knowledge about the basal.” (Participant 2)
“I see the consultant or the nurse often enough to do
that with them…I wouldn’t feel that comfortable
messing with- the insulin ratio- your insulin to carb
ratios… because the ability to look at the data is less so
than in the clinic, if that makes sense.” (Participant 4)
Some individuals, however, highlighted a need for edu-
cation and training to make effective and independent
use of historical CGM data while others, including Par-
ticipant 7, pointed to the potential benefits of including
pattern recognition software with future CGM devices:
“because I can see so many more variants in the line it
makes me more determined to try and work out how to
prevent, like monitor and check and find out why we
have spikes and troughs … I’m at the stage- where at
the moment I can do one change at a time. I know it
just made me more determined to wanna be able to be
in more control with her, working out what settings
need changing, which is why I asked (names hospital)
if they could give me that training.” (Parent 2)
“But it’s difficult to sort of detect the trends, which is
where it’s nice in some software where it- it actually
highlights stuff that it’s noticed.” (Participant 7)
Tolerating and experiencing glitches and inaccuracies
In keeping with findings from previous studies [8, 13,
14, 16] participants reported various glitches and frus-
trations arising from using CGM. These included dif-
ficulties inserting and/or removing the device, finding
a comfortable and discrete place on the body upon
which to locate it, occasional loss of signal and chal-
lenges arising from needing to calibrate their devices
at regular (12 hourly) intervals, especially when they
did not lead routinized lives e.g. due to shift working.
Participants, however, always tempered any criticisms
with positive remarks and all emphasised that the
clinical and psychological benefits of CGM out-
weighed any challenges encountered: “Calibration’s a
pain but, you know, I’ve just got to do it…. And sort
of it’s worth the effort” (Participant 4). Participants
also indicated that that their tolerance of “technical
hitches” (Participant 5) arose partly from their under-
standing that they were in a clinical trial, and their
expectation that, over time, CGM technology would
improve. In some cases, this expectation appeared to
have resulted from earlier experiences of using CGM
and observing developments in its accuracy and
usability:
“and I’ve noticed.. as we’ve taken part in a
lot of trials, these sensors are getting better..
the finger test and the sensor is becoming close
and closer. I remember four, five years ago they
were wide apart. And you thought, ‘well what’s the
point, you know if it’s going to be so widely different.’
So we start seeing an improvement in the technology
and how accurate the sensor’s becoming.” (Parent 5)
Alarms
In general, individuals pointed to clear clinical and psy-
chological benefits to alarms alerting them to high/low
blood glucose:
“It beeps when you’re going high. Having that,
just that- that knowledge that you’ve got something
looking out for you, just in case you do miss it,
is- is so relieving, like ridiculously good… it’s
just- just another level of freedom. You just- you
know you’re safe… yeah, just added security.”
(Participant 9)
Indeed, in one parent’s case, the existence of the alarm
was believed to have saved her young child’s life:
“So, for instance a week ago, em [child’s name has]
never had a hypo at 11 o’clock at night, never.
I heard an alarm going off and thought: what the
hell was that? He’d dropped to 2.2. I wasn’t due to
test [child’s name] until 12 o’clock and I think it
was about 11 o’clock. So I would have left him
another hour, before I tested him. By then, he
could have died or gone into a coma.” (Parent 7)
However, others noted how alarms could result in
poor or interrupted sleep and/or unwelcomed distrac-
tions in the workplace or at school; with various
children, including Parent 1’s daughter, reportedly
switching alarms off in school due to concerns about
drawing attention to themselves and distracting peers:
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“The thing is she can’t really have the alarms at
school cause the teacher is not very happy about her
beeping. So, and if she does she just stops it so the
kids are not looking at her because she’s beeping.
So it doesn’t really have any kind of positive effect,
the alarms during the day. So she would just switch
them off. She doesn’t even check why is it beeping…
Just because she don’t want them going off in school
cause it‘ll draw attention to her.” (Parent 1)
Others described feeling that alarms ‘nagged’ them: “I
suppose the worst of it would be the beeping… its beep-
ing at you to tell you the sensor’s doing something, or
it’s going too low, or something like that, so it nags”
(Participant 3). This ‘nagging’ was described in particu-
larly ambivalent ways by those, such as Participant 6,
who suggested that she did not want to always lead a life
dominated and dictated by her diabetes:
“I kind of love it and I hate it, cause I hate the fact
that it shouted at me all the time. And they’re like
[names health professional] ‘that’s what you want,
so you can make sure you’re ok’. I’m like: ‘not at 3
o’clock in the morning, I don’t care.’” (Participant 6)
For similar reasons, Participant 10 also expressed am-
bivalence; in this individual’s case because the alarms
acted as a tangible and difficult reminder not only that
they had diabetes but also of their struggles to achieve
optimal blood glucose control:
“It goes off a lot, it will vibrate and vibrate, and then
this big alarm will go off… And it wakes me up.
And it goes off in lessons. And it really frustrates me.
And it’s like any diabetic will know if something
annoys you about your diabetes, it’s more than being
annoyed, it’s deep anger…it’s telling me I am high or
it’s telling me I’m low.” (Participant 10)
Data lag
Others noted how, by virtue of the lag between CGM
readings and actual blood glucose levels, they were
sometimes exposed to information which was unhelpful:
“It alerts when I’m going low or I’m going high. So I
do a sugar test: it says 13 the (CGM) reading says I’m
13.5 going up. So it’ll constantly beep… saying you’re
13.6, 13.7, you’re going up, you’re going up. And
actually I’m going down. But it hasn’t caught up with
it yet.” (Participant 13)
Indeed due to this lag and other occasional inaccuracies,
some participants emphasised the importance of
undertaking SMBG before addressing high/low blood glu-
cose: “We don’t rely on it. You know if she’s [teenage
daughter] having a hypo I’d still suggest that she tested”
(Parent 6). Most participants, however, also described
finding the lag relatively unproblematic because of how
they actually made use of CGM data. For instance, it was
noted that the small lag between actual blood glucose
levels and CGM readings was unimportant when retro-
spective analysis of data was undertaken to spot patterns
and trends which could inform changes to pump settings.
In addition, when CGM data prompted participants to
make more immediate changes to prevent high/low blood
glucose, most noted how it was predictive information ra-
ther than actual blood glucose readings which they found
most useful and informative:
“in a way… the arrows are more useful to you than
the actual number because it’s not about what you are
right now, is it. It’s about what’s gonna happen while
you’re asleep, or while you’re going for your run... or
whatever it is, like in a way that’s more helpful to you
in terms of what’s happening next.” (Participant 6)
Discussion and conclusions
This qualitative study has provided an in-depth under-
standing of participants’ experiences of, and views about,
using CGM; and how, and why, CGM can be used to
promote diabetes self-management. In doing so, we have
offered a more detailed and nuanced perspective than is
possible with quantitative/survey research. Specifically,
our findings help explain why high levels of treatment
satisfaction, reported in previous questionnaire studies
[7–9], exist amongst CGM users. As we have shown, this
is not only because CGM allows information about
blood glucose to be accessed instantly and effortlessly,
but also because trend arrows provide insightful infor-
mation that enables diabetes to be managed in more
proactive and effective ways than are possible with
SMBG. Specifically, participants described using trend
arrow information to pre-empt and prevent hyper- and
hypoglycaemia by making proactive and appropriate use
of carbohydrate consumption, corrective doses and
short-term lifestyle planning. Such observations also
help explain clinical research and trial findings that
CGM can reduce hypo and hyperglycaemic excursions
[2, 3, 5] and amplify and support findings of survey
research undertaken with CGM users [22].
Participants also highlighted how CGM offered rich,
informative data which enhanced knowledge of their
blood glucose control at time points (e.g. night-time)
when they were least likely to perform SMBG, and
which could be used to adjust insulin basal rates and/or
mealtime ratios to optimize or improve glycaemic
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control. However, while participants felt confident and
able to make immediate, and what they saw as common-
sense changes to lifestyle, food intake or insulin to
address impending hypo- or hyperglycaemia, most
described feeling much less confident and competent to
undertake retrospective review of CGM data, spot
patterns and trends and use these to inform independent
adjustments to basal rates and mealtime ratios. While
the former observation lends support to Bode and Batte-
lino’s [23] suggestion that CGM usage remains largely
intuitive, the latter raises important questions about
whether the clinical benefits of CGM are always fully
realised. Indeed, in keeping with observations and rec-
ommendations made by others [2, 11, 24] our findings
point to a need for psycho-education and training
amongst those using CGM to make optimal use of this
technology. Specifically, as Ritholz et al. [14] have noted,
we would recommend preparation and follow-up train-
ing about retrospective data use and analysis be given to
individuals using CGM, a training need which has also
been identified in other patient groups using flexible
intensive insulin regimens [25, 26]. To address users’
education and training needs, staff training needs and
workloads may also need to be taken into account [27].
The potential use of technologies, such as pattern recog-
nition software, could also be considered [25]; indeed,
such a recommendation was made by some of those
who took part in this study. Another alternative may be
to consider use of an individualised decision support
system exploiting cloud-based technologies with or with-
out health care professional input [28, 29].
Like others, we found that, while accounts of using
CGM were overwhelmingly positive, participants encoun-
tered some difficulties and hassles using their devices [16].
These included calibration issues, equipment failure and
problems inserting and/or removing the device [30].
While, in keeping with other studies, we found that
disturbance caused by alarms could be a source of annoy-
ance, especially to school-aged children [13, 30], our data
reveal a richer and more complex picture. First, we have
shown that, as well as causing frustration and disrupted
sleep, alarms can also provide comfort and reassurance by
alterting individuals to low (and high) blood glucose in a
timely manner, thereby reinforcing a sense of
hypoglycaemic safety [11]. Second, as our findings also
suggest, some participants’ ambivalence about alarms
appeared to arise from a more general dislike of having
diabetes and an association made between alarming and
what they saw as personal failure to achieve optimal blood
glucose control. This is an issue which could be explored
further in psychological work, to help determine whether
some individuals, especially those with sub-optimal self-
management behaviours and/or a high HbA1c, would
benefit from psychosocial support prior to initiation of
CGM to help maximise the benefits from alarms while
preventing alarm fatigue [31]. However, on a more imme-
diate and practical level, we would recommend that, as
part of CGM training, individuals would benefit from in-
struction on how to switch alarms off and use different
alarm profiles during different parts of the day. In addition,
the snooze time of different alarms should be appropri-
ately set to avoid repeated alarms.
While concerns about sensor inaccuracies and the lag
between recorded and actual blood glucose levels have
been highlighted by others [13], these were not found to
be unduly problematic in the current study. While this
may be due to improvements in CGM technology over
time, we have also shown that participants found CGM
data useful even if, because of the lag, they questioned
the accuracy of readings. This was largely due to partici-
pants valuing predictive (trend arrow) information over
actual readings, and also because retrospective review of
data was not seen as being compromised by a small data
lag. Some participants also emphasised the value of
undertaking SMBG before taking action to address high/
low blood glucose recorded by their sensors, a usage that
may have been reinforced by the education and training
they were given in the run up to the trial.
A key study strength is our use of an open-ended ex-
ploratory design which, as already indicated, offered a
level and depth of insight not possible in clinical and
survey research. An additional strength is the multi-
centre study design and the inclusion of a diverse age
range of individuals in our sample, together with par-
ents of those aged 15 years and under. This potentially
means our findings have greater generalizability than
those of other qualitative studies undertaken to date,
although it should be noted that there is a skew in the
sample towards those aged 31–40 years. Like others,
[11, 14] our sample, which was recruited from a clin-
ical trial, was heavily skewed towards well-educated/
professional individuals, some of whom who had par-
ticipated in earlier studies/trials of CGM. Conse-
quently, such individuals may have been particularly
motivated and interested in diabetes self-care and had
an above average understanding of CGM. In addition,
some participants’ earlier experiences of using CGM,
and of seeing the technology improve over time, may
have resulted in a form of ‘therapeutic optimism’ [32].
Specifically, participants may have hoped or believed
that CGM technology will continue to improve, lead-
ing to overly positive and uncritical accounts. This
may limit the generalizability of our findings; as may
the fact that, in the currently study, only one particular
CGM monitor was used and Polonsky et al.’s [11] ob-
servation that there are notable differences in usability,
reliability and performance of CGM devices. In
addition, we only focused on people’s experiences of
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using CGM for a limited number of weeks and it is
possible that participants might have experienced
fatigue had they used CGM for longer due to frustra-
tions arising from alarms and CGM systems prompting
action as soon as blood glucose moves out of prede-
fined ranges [33, 34]. It should also be noted that, as
we only interviewed people using insulin pumps, the
findings may not be generalizable to those using injec-
tion regimens. For the aforementioned reasons, we
would recommend further qualitative research be
undertaken with more diverse socio-economic groups,
recruited out with clinical trials, who use CGM for
longer periods of time and/or who use multiple daily
injection regimens.
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